# Ellipsys Vascular Access System Post Market Surveillance (PS) Study

Study · id `cardio:ct-nct04484220` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04484220](<https://clinicaltrials.gov/study/NCT04484220>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04484220

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 142 participants.

## Technical summary

Registry record NCT04484220. Allocation not applicable; no masking; primary purpose other. Start 2021-04-13 (actual); primary completion 2025-03-31 (actual). Results posted on 2026-05-07.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose other
- Phase: Not applicable
- Enrolled: 142 participants (enrolled count; ClinicalTrials.gov record NCT04484220, source copy `cardio:ctgov-nct04484220-2026-06-01`, retrieved 2026-10-26)
- Started: 2021-04-13 (actual) (ClinicalTrials.gov record NCT04484220, source copy `cardio:ctgov-nct04484220-2026-06-01`, retrieved 2026-10-26)
- Primary completion: 2025-03-31 (actual) (ClinicalTrials.gov record NCT04484220, source copy `cardio:ctgov-nct04484220-2026-06-01`, retrieved 2026-10-26)
- Completion: 2025-03-31 (actual) (ClinicalTrials.gov record NCT04484220, source copy `cardio:ctgov-nct04484220-2026-06-01`, retrieved 2026-10-26)
- Results first posted: 2026-05-07 (ClinicalTrials.gov record NCT04484220, source copy `cardio:ctgov-nct04484220-2026-06-01`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT04484220, source copy `cardio:ctgov-nct04484220-2026-06-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04484220-2026-06-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Ellipsys Vascular Access System Post Market Surveillance (PS) Study
- Condition: Renal Disease, End Stage
- Condition: Kidney Disease, End-Stage
- Condition: AV Fistula
- Condition: Fistulas Arteriovenous
- Intervention (Device): Ellipsys Vascular Access System
- Lead sponsor: Medtronic Endovascular
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Medtronic Endovascular (`cardio:org-medtronic-endovascular`)

## Provenance

Content hash: 903fcd5b72b21d053da75a32cc3e0511799361e4707c4c8aa315159fbaa6e20f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
